Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma
- Saturday, September 3, 2022, 7:13
- PR Newswire
- Add a comment
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma SAN FRANCISCO, Sept. 3, 2022 /PRNewswire/ — Yingli Pharma (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs…
About the Author
admin has written 20652 stories on this site.